Metraipolis › archive › dc_dc0f866798d1

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived… — Europe PMC PMID:40938473

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40938473
DOI
10.1007/s00280-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-09T23:42:18.632Z
SHA-256 of the archived text
785cca70687db0fe072a2a53df400875baf1497359f00ab0710793673193592c
Stable URL of this page
https://metraipolis.com/documento/dc_dc0f866798d1

How to cite

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived… — Europe PMC PMID:40938473 — Europe PMC (en), https://europepmc.org/article/MED/40938473 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dc0f866798d1 (Metraipolis archive dc_dc0f866798d1, sha256 785cca70687db0fe072a2a53df400875baf1497359f00ab0710793673193592c)
BibTeX
@misc{dcdc0f866798d1,
  title = {RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived… — Europe PMC PMID:40938473},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40938473},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dc0f866798d1; sha256 785cca70687db0fe072a2a53df400875baf1497359f00ab0710793673193592c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40938473. Agents can read the archived copy with the MCP tool read_document.